Search results
COPD Doesn’t Have To Hold You Back – Here’s What To Do After Being Diagnosed
Parade via AOL· 6 months agoMore than 15 million people in the U.S. are affected by COPD (chronic obstructive pulmonary...
COPD patients see promise of new therapies to ease discomfort, aid breathing
United Press International via Yahoo News· 8 months agoRecent advances in chronic obstructive pulmonary disease offer patients more hope in easing...
These Inhalers No Longer Cost More Than $35 Per Month
Verywell Health via Yahoo News· 1 month agoGrace Cary / Getty Images Fact checked by Nick Blackmer Key Takeaways Three major pharmaceutical...
GSK Gears Up for Q3 Earnings: Will It Surpass Estimates?
Zacks via Yahoo Finance· 6 months agoWe expect GSK plc. GSK to beat expectations when it reports third-quarter 2023 results on Nov 1. In...
Theravance's (TBPH) Q2 Earnings Beat, Focus on Pipeline
Zacks via Yahoo Finance· 2 years agoTheravance Biopharma, Inc. TBPH reported adjusted loss (excluding restructuring and related...
Innoviva Inc (INVA) Reports Growth Amidst Challenges in Q4 and Full Year 2023 Financial Results
GuruFocus.com via Yahoo Finance· 2 months agoRevenue: Innoviva Inc (NASDAQ:INVA) reported a 35% year-over-year increase in net product revenues...
GSK to cap out-of-pocket inhaler costs in US
Reuters via Yahoo News· 2 months agoThe cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and...
GSK's Key Drugs to Drive Sales in a Sluggish Second Half
Zacks via Yahoo Finance· 2 years agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta, Shingrix are driving sales, making up...
GSK's New Drugs and Pipeline Hold the Key to Growth in 2023
Zacks via Yahoo Finance· 1 year agoGSK's specialty products like Dovato, Nucala, Trelegy Ellipta and Shingrix are likely to drive...
Theravance (TBPH) Q3 Loss Narrower Than Expected, Sales Miss
Zacks via Yahoo Finance· 1 year agoTheravance Biopharma, Inc. TBPH reported third-quarter 2022 net loss of 21 cents per share, narrower...